Over the last 25 years the use of auto- and allogeneic HSCT for NHL increased dramatically. This therapy is being used for types of NHL that were not even defined when transplantation was first used. Although thousands of NHL patients have had their lives prolonged or have been cured with transplantation, the role of HSCT is still undefined in most situations. Unfortunately, HSCT is often used simply because satisfactory nontransplant options are unavailable. Allogeneic HSCT is often used because of the perception that autologous HSCT will be ineffective. Reduced-intensity allogeneic HSCT is often utilized in situations when definite evidence of superiority over myeloablative allogeneic HSCT, and even autologous HSCT, do not exist. Treatment decisions are even more difficult today because of better primary treatments and because of the introduction of effective new agents and targeted therapies for relapsed and refractory disease. It is hoped that the role of HSCT for NHL will be refined when results of ongoing phase III trials are available.
ASJC Scopus subject areas
- Cancer Research